Mavrilimumab - CSL/Kiniksa Pharmaceuticals
Alternative Names: Anti-GM-CSFR monoclonal antibody - MedImmune; CAM-3001; KPL-301Latest Information Update: 05 Nov 2023
At a glance
- Originator Zenyth Therapeutics
- Developer Kiniksa Pharmaceuticals; MedImmune
- Class Anti-infectives; Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Granulocyte-macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cardiovascular disorders
Highest Development Phases
- Phase II Giant cell arteritis
- Phase I Cardiovascular disorders
- Discontinued Inflammation; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 01 Nov 2022 Mavrilimumab - CSL/Kiniksa Pharmaceuticals is available for licensing as of 01 Nov 2022. www.kiniksa.com 9372285
- 19 Aug 2022 Phase-I clinical trials in Cardiovascular disorders in USA (unspecified route), as of August 2022 (Kiniksa Pharmaceuticals pipeline, August 2022)
- 01 Jun 2022 Pharmacodynamics data from preclinical studies in Giant cell arteritis at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)